This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| STAP cell | |
|---|---|
| Name | STAP cell |
| Discovered | 2014 |
| Discoverers | Haruko Obokata; other authors |
| Institutions | RIKEN; University of Tokyo; Harvard University; Waseda University |
| Field | Cell biology; Stem cell research |
STAP cell Stimulus-triggered acquisition of pluripotency (commonly known by the abbreviation STAP) was a 2014 claim that somatic cells could be reprogrammed to a pluripotent state by exposure to simple stressors. The announcement generated rapid attention across Nature, The New York Times, and institutional press offices, prompted global replication attempts, and culminated in high-profile investigations involving RIKEN, Harvard Medical School, and the Japanese government. The episode became a landmark case intersecting laboratory practice, publication ethics, scientific reproducibility, and institutional oversight.
The STAP story arose in the context of ongoing discourse about cellular reprogramming following breakthroughs by Shinya Yamanaka and the awarding of the Nobel Prize in Physiology or Medicine for induced pluripotent stem cells. Interest among institutions such as RIKEN, Kyoto University, University of Cambridge, Massachusetts Institute of Technology, and Stanford University focused on low-barrier methods to induce pluripotency that could complement work by John Gurdon and Yamanaka. Prominent groups in Japan and United States laboratories examined chemical reprogramming and stress responses, and journals including Nature and Cell were central venues for debate. Funders like the Japan Society for the Promotion of Science and the National Institutes of Health monitored developments in regenerative medicine and translational research.
Two 2014 papers published in Nature listed Haruko Obokata as first author and senior authors affiliated with RIKEN and included collaborators from institutions associated with Harvard University and Waseda University. The articles claimed that exposure of mature cells to acid or mechanical stress produced pluripotent cells capable of contributing to embryos and generating chimeras, with supporting images, lineage tracing, and gene expression data. Coverage by media outlets such as The New York Times, BBC News, and Nature News amplified the claims, while commentary from figures like Shinya Yamanaka and John Gurdon emphasized both potential and skepticism. The publications immediately prompted responses from editorial teams at Nature and drove scrutiny by the broader communities at European Molecular Biology Laboratory and Howard Hughes Medical Institute-affiliated labs.
The authors described protocols involving exposure of splenic lymphocytes, fibroblasts, and other somatic cell types to transient acidic conditions or physical stress, followed by culture under conditions associated with pluripotency markers like Oct4. They reported contributions to preimplantation embryos and generation of chimeric offspring, supported by microscopy, immunostaining, and PCR-based assays. Methods referenced standards used in embryology labs at institutions such as Kyoto University and Cambridge University Hospitals and invoked comparisons with techniques from Yamanaka-derived induced pluripotent stem cell protocols. The papers asserted reproducibility across cell types and suggested potential applications in regenerative therapies, prompting immediate interest from clinical centers and venture groups.
Within weeks, groups at Harvard University, Stanford University, University of Tokyo, University of Cambridge, Imperial College London, Max Planck Society, and dozens of independent laboratories attempted to reproduce the STAP protocols. Many posted negative results on preprint servers and institutional blogs, and formal correspondence to journals documented inability to obtain key outcomes such as reliable expression of pluripotency markers or contribution to chimeras. Collaborative replication efforts coordinated by research networks, including laboratories linked to Waseda University and RIKEN, often failed, and disagreements arose over methodological details, materials, and cell-source provenance. The replication crisis prompted commentaries in outlets like Nature News and reports by oversight bodies in Japan and abroad.
Following allegations of image manipulation and data irregularities, RIKEN launched an internal inquiry while journals reviewed the publications. Investigations implicated duplicated microscopy panels, questionable lineage-tracing evidence, and inconsistencies in experimental records. Committees convened at RIKEN, Waseda University, and other institutions evaluated authorship practices and data provenance; some findings led to retractions of the Nature papers. The RIKEN investigation report and related institutional determinations cited breaches of research integrity, and the dispute involved prominent figures in Japanese science policy and regulatory oversight. Consequences included resignations, public apologies, and disciplinary actions consistent with policies at RIKEN and national frameworks overseen by bodies like the Ministry of Education, Culture, Sports, Science and Technology (Japan).
The STAP episode affected discourse in regenerative medicine at centers including Kyoto University, Harvard Medical School, University of Oxford, and University of California, San Francisco. It stimulated reforms around data sharing, image handling standards, and pre-publication verification promoted by publishers such as Nature and Science. Bioethicists at institutions like Princeton University and University College London debated authorship responsibility, mentorship, and whistleblower protections. Funding agencies and oversight boards revised guidance on reproducibility, and the case informed training modules at research institutions and professional societies including the International Society for Stem Cell Research.
The fallout led to institutional reviews by RIKEN, administrative actions involving investigators, and scrutiny by funding agencies and university governance bodies. Some coauthors faced career impacts, and RIKEN implemented structural changes to research governance and quality control consistent with national policy discussions involving the National Diet and ministries engaged with science policy. International collaborators and host institutions reviewed collaborations and data management practices, affecting grant reporting to agencies such as the Japan Society for the Promotion of Science and the National Institutes of Health. The STAP case remains a reference point in discussions of research integrity, laboratory oversight, and the responsibilities of journals, institutions, and investigators in high-profile biomedical claims.